BRAF and cancer: BRAF-V600E-mutant cancers with underlying mismatch repair deficiency are likely to be resistant to FU-based therapy and may require different combination treatment strategies, possibly with addition of immunotherapy.25 The establishment of a model to study immunotherapies in an immune-organoid coculture system is an exciting field to pursue.30,31 Thus, organoid models can be a powerful tool to investigate combinations and sequential treatment regimens aimed at maximizing response and minimizing chance of acquired resistance.